Controls serum phosphorus. ANDA 207624, held by Aurobindo Pharma. Sevelamer Carbonate.
As of Nov 16, 2026, ANDA 207624 (Sevelamer Carbonate), held by Aurobindo Pharma, was first approved by FDA on Jun 13, 2017, with 2 approved supplements and 0 published complete response letters.
Sevelamer carbonate for oral suspension is indicated for the control of serum phosphorus in adults and children 6 years of age and older with chronic kidney disease (CKD) on dialysis.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 13, 2017 | Original application | Approved |
| Sevelamer Carbonate800MG/PACKET · for suspension;oral | Sevelamer Carbonate | Rx |
| Sevelamer Carbonate2.4GM/PACKET · for suspension;oral | Sevelamer Carbonate | Rx |
| Apr 5, 2022 | Supplement 3Labeling · Standard review | Approved | None posted |
| Mar 25, 2020 | Supplement 1Labeling · Standard review | Approved | None posted |
| Jun 13, 2017 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters